| Prev Close | 224.77 |
| Day Low/High | 223.08 / 225.65 |
| 52 Wk Low/High | 184.50 / 256.80 |
| Avg Volume | 2.02M |
| Exchange | NYSE |
| Shares Outstanding | 334.31M |
| Market Cap | 75.14B |
| EPS | 38.20 |
| P/E Ratio | N/A |
| Div & Yield | 2.80 (1.20%) |
Latest News
Valeant CEO Confident Divestitures Can Successfully Pare Debt, Skeptics Remain
For his 'Executive Decision' segment, Cramer again sat down with Joe Papa, chairman and CEO of Valeant
PayPal, Marriott International, Randgold Resources: 'Mad Money' Lightning Round
Jim Cramer is bullish on PayPal, Marriott International, Randgold Resources, and Kirkland Lake.
The Market Is Not About Washington: Cramer's 'Mad Money' Recap (Wed 8/16/17)
Jim Cramer says despite chaos in Washington, the market's not falling. Why? Because stocks aren't a referendum on the presidency.
Valeant Pharmaceuticals: Cramer's Top Takeaways
Joe Papa, chairman and CEO of Valeant Pharmaceuticals International, talks to Jim Cramer about his company's turnaround.
Black, Jewish Goldman Executive Sues Firm Over Discriminatory Practices
A Goldman spokesman said that the firm believes the case is 'without merit' and that they will 'vigorously contest it.'
Teva Is Cheap, Not Dead
The drug stock deserved to go down, but the resulting selloff is an overreaction.
ALLERGAN SHAREHOLDER ALERT By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Allergan, Inc. - (AGN)
Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C.
Weekly Roundup
Markets see volatility as geopolitical tensions rise. We closed out one tech position and initiated another.
Opioid Makers Buffeted by Trump's Declaration of Addiction Crisis
The companies are subject to either state, federal or congressional inquiries into their marketing practices for prescription opioids, which are blamed for helping to fuel rising numbers or addicted individuals.
Blame the Millennials: Cramer's 'Mad Money' Recap (Wednesday 8/9/17)
Jim Cramer says we must watch the 'selfie generation' because it's changing the ways companies do business.
Valeant and Teva Share Similar Ambitions With Similar Pitfalls
Here's what you need to know now for Wed., Aug. 9.
It's Time to Talk About the Russell 2000
There are 2 ways for small-caps to go, and neither one is up.
Allergan: Cramer's Top Takeaways
Brent Saunders, chairman and CEO of Allergan, tells Jim Cramer he's bullish on new treatments for depression.
Buy These High-Octane Stocks on a Dip: Cramer's 'Mad Money' Recap (Monday 8/7/17)
Jim Cramer says history doesn't have to repeat itself. You don't want to miss another opportunity in the highly visible FANG-style stocks.
Small-Cap Turnaround Stories
When one of these pays off, it can make up for a number of errant wagers.
FDA Approves Medicines360's SNDA For LILETTA® (levonorgestrel-releasing Intrauterine System) 52 Mg To Prevent Pregnancy For Up To Four Years
- Approval Offers Women Additional Flexibility for Pregnancy Prevention -
Are You Brave Enough to Buy Low?
'Buy low and sell high' is easier said than done, but you can fight your fear with TEVA.
Action Alerts PLUS: There's Strength in (Earnings) Numbers
Callout: Results and guidance lift markets, dodging D.C. drama.
